NewsDialy
The short version is that Eli Lilly and Company secured approval for a breast cancer treatment combination.
In plain terms, a drug combination is a therapeutic strategy that pairs two distinct agents to treat a disease, often aiming to improve outcomes or manage resistance compared to a single drug.
This approval represents a significant regulatory milestone for the pharmaceutical giant in the oncology space.
What this actually says is that the regulatory body has reviewed the clinical data and determined the therapy meets the standards for safety and efficacy required for market access.
Keep reading